BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30547223)

  • 1. [CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
    Prinz J; d'Hargues Y; Gödel P; Shimabukuro-Vornhagen A; Kochanek M; Böll B
    Med Klin Intensivmed Notfmed; 2020 Apr; 115(3):198-204. PubMed ID: 30547223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T-cell therapy and critical care : A survival guide for medical emergency teams.
    Messmer AS; Que YA; Schankin C; Banz Y; Bacher U; Novak U; Pabst T
    Wien Klin Wochenschr; 2021 Dec; 133(23-24):1318-1325. PubMed ID: 34613477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 4. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.
    Pabst T; Joncourt R; Shumilov E; Heini A; Wiedemann G; Legros M; Seipel K; Schild C; Jalowiec K; Mansouri Taleghani B; Fux M; Novak U; Porret N; Zeerleder S; Bacher U
    Exp Hematol; 2020 Aug; 88():7-14.e3. PubMed ID: 32673688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
    Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
    Front Immunol; 2021; 12():707191. PubMed ID: 34349766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
    Aldoss I; Khaled SK; Budde E; Stein AS
    Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
    Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
    Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
    Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
    Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children].
    Yang F; Wang TY; DU WW; He HL; Xiao PF; Lu Y; Hu SY; Li BS; Lu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):718-725. PubMed ID: 35680795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
    Zhang Y; Zhou F; Wu Z; Li Y; Li C; Du M; Luo W; Kou H; Lu C; Mei H
    Front Immunol; 2022; 13():914959. PubMed ID: 35799791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
    Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
    J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
    Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
    J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review).
    Kausar MA; Anwar S; El-Horany HE; Khan FH; Tyagi N; Najm MZ; Sadaf ; Eisa AA; Dhara C; Gantayat S
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37830150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.